PROMIS NEUROSCIENCES INC (PMN) Stock Price, Quote, News and Overview
NASDAQ:PMN - Nasdaq - CA74346M4065 - Common Stock - Currency: USD
PMN Quote, Performance and Key Statistics
NASDAQ:PMN (4/25/2025, 8:00:00 PM)
0.5884
+0.03 (+4.88%)
The current stock price of PMN is 0.5884 USD. In the past month the price decreased by -15.94%. In the past year, price decreased by -70.28%.
PMN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.39 | 329.14B | ||
| AMGN | AMGEN INC | 14.17 | 150.99B | ||
| GILD | GILEAD SCIENCES INC | 13.33 | 128.61B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1702.9 | 126.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.2 | 65.88B | ||
| ARGX | ARGENX SE - ADR | 330.52 | 37.54B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.72B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.39B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.52B | ||
| NTRA | NATERA INC | N/A | 20.79B | ||
| BIIB | BIOGEN INC | 7.22 | 17.39B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.30B |
Related stock screener links
About PMN
Company Profile
ProMIS Neurosciences, Inc. engages in the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases. The company is headquartered in Toronto, Ontario. The company went IPO on 2017-04-03. The company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.
Company Info
PROMIS NEUROSCIENCES INC
Suite 200, 1920 Yonge Street
TORONTO ONTARIO CA
Employees: 7
Company Website: https://www.promisneurosciences.com/
Investor Relations: http://www.promisneurosciences.com/investors
Phone: 14168476898
PROMIS NEUROSCIENCES INC / PMN FAQ
What is the stock price of PROMIS NEUROSCIENCES INC today?
The current stock price of PMN is 0.5884 USD. The price increased by 4.88% in the last trading session.
What is the ticker symbol for PROMIS NEUROSCIENCES INC stock?
The exchange symbol of PROMIS NEUROSCIENCES INC is PMN and it is listed on the Nasdaq exchange.
On which exchange is PMN stock listed?
PMN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for PROMIS NEUROSCIENCES INC stock?
7 analysts have analysed PMN and the average price target is 7.14 USD. This implies a price increase of 1113.46% is expected in the next year compared to the current price of 0.5884. Check the PROMIS NEUROSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is PROMIS NEUROSCIENCES INC worth?
PROMIS NEUROSCIENCES INC (PMN) has a market capitalization of 19.23M USD. This makes PMN a Nano Cap stock.
How many employees does PROMIS NEUROSCIENCES INC have?
PROMIS NEUROSCIENCES INC (PMN) currently has 7 employees.
What are the support and resistance levels for PROMIS NEUROSCIENCES INC (PMN) stock?
PROMIS NEUROSCIENCES INC (PMN) has a support level at 0.59 and a resistance level at 0.64. Check the full technical report for a detailed analysis of PMN support and resistance levels.
Should I buy PROMIS NEUROSCIENCES INC (PMN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PMN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PMN, evaluating the profitability, health, valuation and growth aspects
- PROMIS NEUROSCIENCES INC (PMN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PROMIS NEUROSCIENCES INC (PMN) Sales and EPS estimates to see what analysts future expectations are.
- PROMIS NEUROSCIENCES INC (PMN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PROMIS NEUROSCIENCES INC (PMN) Insider and Institutional Ownership to learn about the owners and their transactions.
- PROMIS NEUROSCIENCES INC (PMN) Stock Chart to make your own analysis
- PROMIS NEUROSCIENCES INC (PMN) Latest news and press-releases to stay up to date.
Does PROMIS NEUROSCIENCES INC (PMN) stock pay dividends?
PMN does not pay a dividend.
When does PROMIS NEUROSCIENCES INC (PMN) report earnings?
PROMIS NEUROSCIENCES INC (PMN) will report earnings on 2025-05-20.
What is the Price/Earnings (PE) ratio of PROMIS NEUROSCIENCES INC (PMN)?
The PE ratio for PROMIS NEUROSCIENCES INC (PMN) is 6.54. This is based on the reported non-GAAP earnings per share of 0.09 and the current share price of 0.5884 USD. Check the full fundamental report for a full analysis of the valuation metrics for PMN.
What is the Short Interest ratio of PROMIS NEUROSCIENCES INC (PMN) stock?
The outstanding short interest for PROMIS NEUROSCIENCES INC (PMN) is 0.75% of its float. Check the ownership tab for more information on the PMN short interest.
PMN Technical Analysis
PMN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to PMN. PMN has a great financial health rating, but its profitability evaluates not so good.
PMN Financial Highlights
Over the last trailing twelve months PMN reported a non-GAAP Earnings per Share(EPS) of 0.09. The EPS increased by 98.63% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | 14.69% | ||
| ROE | 16.85% | ||
| Debt/Equity | 0 |
PMN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to PMN. The Buy consensus is the average rating of analysts ratings from 7 analysts.